Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Conditions
Interventions
Levonorgestrel (LNG)
Locations
18
United States
2701 Northwestern University CRS
Chicago, Illinois, United States
Rush Univ. Med. Ctr. ACTG CRS (2702)
Chicago, Illinois, United States
Weill Cornell Upton CRS (7803)
New York, New York, United States
Unc Aids Crs (3201)
Chapel Hill, North Carolina, United States
Hosp. of the Univ. of Pennsylvania CRS (6201)
Philadelphia, Pennsylvania, United States
Pitt CRS (1001)
Pittsburgh, Pennsylvania, United States
Start Date
May 6, 2019
Primary Completion Date
November 2, 2020
Completion Date
November 30, 2020
Last Updated
December 27, 2021
NCT06627764
NCT06192160
NCT05947890
NCT05989802
NCT04142047
NCT06694805
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions